GLP-1 Drug Pegsebrenatide Enters Phase 2 Trial to Slow Progressive MS Brain Loss
A GLP-1 receptor agonist targeting neuroinflammation is now in a 120-patient trial measuring brain volume preservation in progressive MS.
Summary
A new clinical trial is testing whether pegsebrenatide, a long-acting GLP-1 receptor agonist, can slow brain shrinkage and disability progression in people with progressive multiple sclerosis. The TAG-MS study, led by Johns Hopkins and running across multiple academic centers, will enroll about 120 patients for nearly two years. The drug works by reducing neuroinflammation and protecting neurons — mechanisms relevant beyond MS to broader brain aging. Earlier data from a Parkinson's trial hinted at slower motor decline, especially in younger patients. The primary measure is brain volume loss on MRI, a key marker of neurodegeneration. This trial adds to growing evidence that GLP-1 drugs may have significant neuroprotective effects beyond their well-known metabolic benefits.
Detailed Summary
Neuraly has dosed its first patient in a Phase 2 trial of pegsebrenatide for progressive multiple sclerosis, marking a significant step in exploring GLP-1 receptor agonists as neuroprotective agents. The trial, called TAG-MS, is investigator-initiated and led by Dr. Ellen Mowry at Johns Hopkins University, lending it strong academic credibility.
The study will enroll approximately 120 patients randomized equally to weekly pegsebrenatide injections or placebo for 96 weeks. Its primary endpoint is change in normalized brain parenchymal volume — essentially how much brain tissue is preserved — measured by MRI. Secondary endpoints include gray matter volume, thalamic volume, cortical thickness, and disability scores, creating a comprehensive neurodegeneration picture.
Pegsebrenatide is an analog of exendin-4, engineered for extended action at the GLP-1 receptor. Unlike metabolic GLP-1 drugs like semaglutide, this compound is specifically designed to cross into the central nervous system and dampen neuroinflammation. Preclinical models showed it could slow disease progression, and a prior Phase 2 trial in 255 Parkinson's patients suggested slower motor decline, with stronger effects in patients under 60.
For longevity-focused readers, this trial matters beyond MS. Neuroinflammation is a central driver of brain aging, cognitive decline, and multiple neurodegenerative diseases. If pegsebrenatide demonstrates meaningful brain volume preservation, it could inform broader neuroprotective strategies. The GLP-1 pathway is already reshaping metabolic medicine; its potential role in slowing brain aging represents a major frontier.
Caveats apply: this is an early-phase trial with results years away, and Phase 2 trials frequently fail to replicate in larger studies. The Parkinson's signal was modest and in a specific age subgroup. Still, the mechanistic rationale is strong, the trial design is rigorous, and the endpoints are clinically meaningful biomarkers of neurodegeneration.
Key Findings
- Pegsebrenatide targets neuroinflammation via GLP-1 receptors, a mechanism relevant to broad brain aging beyond MS.
- 120-patient double-blind trial runs 96 weeks with brain volume loss on MRI as the primary endpoint.
- Prior Parkinson's Phase 2 data showed slower motor decline, especially in patients under age 60.
- GLP-1 receptor agonists may offer neuroprotection independent of their metabolic and weight-loss effects.
- Thalamic volume and cortical thickness are secondary endpoints — key biomarkers of neurodegeneration and cognitive aging.
Methodology
This is a news report summarizing a company announcement about a newly initiated Phase 2 clinical trial. The source, Longevity.Technology, is a credible longevity-focused outlet. Evidence basis includes preclinical data and a prior Phase 2 Parkinson's trial; full peer-reviewed results are not yet available.
Study Limitations
Results are years away and Phase 2 trials have high failure rates; the Parkinson's signal was modest and age-restricted. The announcement is company-issued and has not been independently peer-reviewed. Readers should verify trial details at ClinicalTrials.gov under NCT07497399.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.